Update Breast Cancer 2020 Part 1 - Early Breast Cancer
Standard
Update Breast Cancer 2020 Part 1 - Early Breast Cancer : Consolidation of Knowledge About Known Therapies. / Schneeweiss, Andreas; Hartkopf, Andreas D; Müller, Volkmar; Wöckel, Achim; Lux, Michael P; Janni, Wolfgang; Ettl, Johannes; Belleville, Erik; Huober, Jens; Thill, Marc; Fasching, Peter A; Kolberg, Hans-Christian; Pöschke, Patrik; Welslau, Manfred; Overkamp, Friedrich; Tesch, Hans; Fehm, Tanja N; Lüftner, Diana; Schütz, Florian.
In: GEBURTSH FRAUENHEILK, Vol. 80, No. 3, 03.2020, p. 277-287.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Update Breast Cancer 2020 Part 1 - Early Breast Cancer
T2 - Consolidation of Knowledge About Known Therapies
AU - Schneeweiss, Andreas
AU - Hartkopf, Andreas D
AU - Müller, Volkmar
AU - Wöckel, Achim
AU - Lux, Michael P
AU - Janni, Wolfgang
AU - Ettl, Johannes
AU - Belleville, Erik
AU - Huober, Jens
AU - Thill, Marc
AU - Fasching, Peter A
AU - Kolberg, Hans-Christian
AU - Pöschke, Patrik
AU - Welslau, Manfred
AU - Overkamp, Friedrich
AU - Tesch, Hans
AU - Fehm, Tanja N
AU - Lüftner, Diana
AU - Schütz, Florian
PY - 2020/3
Y1 - 2020/3
N2 - This review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.
AB - This review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.
U2 - 10.1055/a-1111-2431
DO - 10.1055/a-1111-2431
M3 - SCORING: Journal article
C2 - 32139917
VL - 80
SP - 277
EP - 287
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 3
ER -